HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Isla, A. Articles by Pedraz, J. L. Search for Related Content PubMed PubMed Citation Articles by Isla, A. Articles by Pedraz, J. L. Social Bookmarking                         What's this?

Meropenem and Continuous Renal Replacement Therapy: In Vitro Permeability of 2 Continuous Renal Replacement Therapy Membranes and Influence of Patient Renal Function on the Pharmacokinetics in Critically Ill Patients

From the Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country, Vitoria-Gasteiz, Spain (Ms Isla, Dr Gascón, Ms Arzuaga, and Dr Pedraz), the Intensive Care Unit, Santiago Apóstol Hospital, Vitoria-Gasteiz, Spain (Drs Maynar and Corral), and the Intensive Care Unit, Doce de Octubre Hospital, Madrid, Spain (Dr Sánchez-Izquierdo).

The pharmacokinetics of meropenem were characterized in 20 patients with different degrees of renal function who underwent continuous renal replacement therapy. Previously, no differences were detected in vitro in the removal of meropenem by continuous venovenous hemofiltration or continuous venovenous hemodialysis or when AN69 or polysulfone membranes were compared. In patients, no significant differences in the sieving coefficient or the saturation coefficient with the renal function were found, and the mean sieving coefficient/saturation coefficient value (0.80 ± 0.12) was similar to the unbound fraction (0.79 ± 0.08). An increase in total clearance and a decrease in elimination half-life were observed to the extent that the patient's creatinine clearance was higher. Likewise, the contribution of continuous renal replacement therapy to total clearance diminished in patients with less renal impairment. The results suggest that the renal function of the patient may influence meropenem pharmacokinetics during continuous renal replacement therapy. The lower trough plasma levels observed in nonrenal patients would not lead to adequate time during which serum drug concentrations are above the minimum inhibitory concentration values in many infections.

Key Words: Continuous renal replacement therapies • meropenem • pharmacokinetics • critically ill

Address for reprints: Dr José Luis Pedraz Muñoz, Laboratorio de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia. Paseo de la Universidad no 7. 01006 Vitoria-Gasteiz, Spain.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. M. M. Y. Li, C. D. Gomersall, G. Choi, Q. Tian, G. M. Joynt, and J. Lipman A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data? J. Antimicrob. Chemother., November 1, 2009; 64(5): 929 - 937. [Abstract] [Full Text] [PDF]